STAT+: Are analysts too quick to gloss over Lilly’s liver case?

Vertex Pharma reported first-quarter earnings and shelved an early stage therapy for cystic fibrosis due to poor tolerability. Cytokinetics' drug Myqorzo met efficacy goals in a study of genetic heart disease. Viridian Therapeutics announced positive results from a Phase 3 study of its drug elegrobart.